JP2018525430A5 - - Google Patents

Download PDF

Info

Publication number: JP2018525430A5
Authority: JP; Japan
Prior art keywords: optionally substituted; alkyl; nhr; group; aryl
Prior art date: 2016-08-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2018511057A

Other languages

English (en)

Japanese (ja)

Other versions

JP2018525430A (ja

JP7334041B2 (ja

Filing date

2016-08-25

Publication date

2019-10-10

2016-08-25 Application filed filed Critical

2016-08-25 Priority claimed from PCT/NZ2016/050135 external-priority patent/WO2017034420A1/en

2018-09-06 Publication of JP2018525430A publication Critical patent/JP2018525430A/ja

2019-10-10 Publication of JP2018525430A5 publication Critical patent/JP2018525430A5/ja

2021-11-08 Priority to JP2021182007A priority Critical patent/JP2022033753A/ja

2023-08-28 Application granted granted Critical

2023-08-28 Publication of JP7334041B2 publication Critical patent/JP7334041B2/ja

Status Active legal-status Critical Current

2036-08-25 Anticipated expiration legal-status Critical

Links

125000000217 alkyl group Chemical group 0.000 claims 60
125000003107 substituted aryl group Chemical group 0.000 claims 44
229910052757 nitrogen Inorganic materials 0.000 claims 32
125000001424 substituent group Chemical group 0.000 claims 31
125000003118 aryl group Chemical group 0.000 claims 30
125000001072 heteroaryl group Chemical group 0.000 claims 29
239000008194 pharmaceutical composition Substances 0.000 claims 22
125000004122 cyclic group Chemical group 0.000 claims 21
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 16
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 16
150000001204 N-oxides Chemical class 0.000 claims 15
125000004432 carbon atom Chemical group C* 0.000 claims 15
229910052717 sulfur Inorganic materials 0.000 claims 15
125000005842 heteroatom Chemical group 0.000 claims 14
125000005843 halogen group Chemical group 0.000 claims 13
229910052760 oxygen Inorganic materials 0.000 claims 13
229910052736 halogen Inorganic materials 0.000 claims 11
150000002367 halogens Chemical class 0.000 claims 11
125000002883 imidazolyl group Chemical group 0.000 claims 10
125000002757 morpholinyl group Chemical group 0.000 claims 10
125000004568 thiomorpholinyl group Chemical group 0.000 claims 10
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
-1 C 3-7 cyclic alkyl Chemical group 0.000 claims 8
125000003282 alkyl amino group Chemical group 0.000 claims 8
125000003725 azepanyl group Chemical group 0.000 claims 8
125000006165 cyclic alkyl group Chemical group 0.000 claims 8
229910052739 hydrogen Inorganic materials 0.000 claims 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
125000004193 piperazinyl group Chemical group 0.000 claims 8
125000003386 piperidinyl group Chemical group 0.000 claims 8
125000000719 pyrrolidinyl group Chemical group 0.000 claims 8
101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims 6
125000003342 alkenyl group Chemical group 0.000 claims 6
125000000304 alkynyl group Chemical group 0.000 claims 6
125000002393 azetidinyl group Chemical group 0.000 claims 6
150000001875 compounds Chemical class 0.000 claims 5
101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims 4
101100516572 Caenorhabditis elegans nhr-8 gene Proteins 0.000 claims 4
150000003839 salts Chemical class 0.000 claims 4
229920006395 saturated elastomer Polymers 0.000 claims 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
101100240519 Caenorhabditis elegans nhr-13 gene Proteins 0.000 claims 2
102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 2
101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 2
101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims 2
102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 claims 2
208000015114 central nervous system disease Diseases 0.000 claims 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
125000000547 substituted alkyl group Chemical group 0.000 claims 2
208000024891 symptom Diseases 0.000 claims 2
ONXJSWCJGQDQRB-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(2-chlorophenyl)urea Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)NC3=C(Cl)C=CC=C3)=NOC2=N1 ONXJSWCJGQDQRB-UHFFFAOYSA-N 0.000 claims 1
GUVHHBAQYNDOQA-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(2-methoxyphenyl)urea Chemical compound COC1=C(NC(=O)NC2=NOC3=NC(C)=C(Cl)C(C)=C23)C=CC=C1 GUVHHBAQYNDOQA-UHFFFAOYSA-N 0.000 claims 1
ZKPMHNKZZRXJEU-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(3-chlorophenyl)urea Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)NC3=CC(Cl)=CC=C3)=NOC2=N1 ZKPMHNKZZRXJEU-UHFFFAOYSA-N 0.000 claims 1
HTHMACSUVRONRQ-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(3-methoxyphenyl)urea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=CC(=CC=C1)OC)C HTHMACSUVRONRQ-UHFFFAOYSA-N 0.000 claims 1
OYTMNZZKMAODFF-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(4-chlorophenyl)urea Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)NC3=CC=C(Cl)C=C3)=NOC2=N1 OYTMNZZKMAODFF-UHFFFAOYSA-N 0.000 claims 1
LLIPTOCUBJBVQM-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(4-cyanophenyl)urea Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)NC3=CC=C(C=C3)C#N)=NOC2=N1 LLIPTOCUBJBVQM-UHFFFAOYSA-N 0.000 claims 1
KXVLEJZIDZJGTN-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(4-methoxyphenyl)urea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=CC=C(C=C1)OC)C KXVLEJZIDZJGTN-UHFFFAOYSA-N 0.000 claims 1
LJPBPWSBAAEXGB-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-[2-(trifluoromethoxy)phenyl]urea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=C(C=CC=C1)OC(F)(F)F)C LJPBPWSBAAEXGB-UHFFFAOYSA-N 0.000 claims 1
YTGNWVMCEAAABQ-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-[2-(trifluoromethyl)phenyl]urea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=C(C=CC=C1)C(F)(F)F)C YTGNWVMCEAAABQ-UHFFFAOYSA-N 0.000 claims 1
XLOUIZLWOJHUTJ-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-[3-(trifluoromethoxy)phenyl]urea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=CC(=CC=C1)OC(F)(F)F)C XLOUIZLWOJHUTJ-UHFFFAOYSA-N 0.000 claims 1
NTNKYXWAKJZYDN-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-[3-(trifluoromethyl)phenyl]urea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=CC(=CC=C1)C(F)(F)F)C NTNKYXWAKJZYDN-UHFFFAOYSA-N 0.000 claims 1
MKMUEPQDBRDIPR-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-[4-(trifluoromethoxy)phenyl]urea Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)NC3=CC=C(OC(F)(F)F)C=C3)=NOC2=N1 MKMUEPQDBRDIPR-UHFFFAOYSA-N 0.000 claims 1
VVWRXPJEKFZHMF-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-[4-(trifluoromethyl)phenyl]urea Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)NC3=CC=C(C=C3)C(F)(F)F)=NOC2=N1 VVWRXPJEKFZHMF-UHFFFAOYSA-N 0.000 claims 1
OCTHIRRMTADGPR-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-phenylurea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=CC=CC=C1)C OCTHIRRMTADGPR-UHFFFAOYSA-N 0.000 claims 1
206010002091 Anaesthesia Diseases 0.000 claims 1
208000002177 Cataract Diseases 0.000 claims 1
208000028698 Cognitive impairment Diseases 0.000 claims 1
208000035473 Communicable disease Diseases 0.000 claims 1
241001465754 Metazoa Species 0.000 claims 1
LQPAECYCNSYMPR-UHFFFAOYSA-N N-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-2-phenylacetamide Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)CC3=CC=CC=C3)=NOC2=N1 LQPAECYCNSYMPR-UHFFFAOYSA-N 0.000 claims 1
XOYBTIIRRPALOP-UHFFFAOYSA-N N-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)acetamide Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(C)=O)C XOYBTIIRRPALOP-UHFFFAOYSA-N 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 claims 1
230000037005 anaesthesia Effects 0.000 claims 1
201000011510 cancer Diseases 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
208000020832 chronic kidney disease Diseases 0.000 claims 1
208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
208000010877 cognitive disease Diseases 0.000 claims 1
208000029078 coronary artery disease Diseases 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
210000004996 female reproductive system Anatomy 0.000 claims 1
230000002757 inflammatory effect Effects 0.000 claims 1
239000000203 mixture Substances 0.000 claims 1
MPAJLQMQYTTZSB-UHFFFAOYSA-N n-[6-phenyl-4-(trifluoromethyl)-[1,2]oxazolo[5,4-b]pyridin-3-yl]cyclopropanecarboxamide Chemical compound C1=2C(C(F)(F)F)=CC(C=3C=CC=CC=3)=NC=2ON=C1NC(=O)C1CC1 MPAJLQMQYTTZSB-UHFFFAOYSA-N 0.000 claims 1

JP2018511057A 2015-08-27 2016-08-25 トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用 Active JP7334041B2 (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP2021182007A JP2022033753A (ja)	2015-08-27	2021-11-08	トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
NZ71151415		2015-08-27
NZ711514		2015-08-27
PCT/NZ2016/050135 WO2017034420A1 (en)	2015-08-27	2016-08-25	Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2021182007A Division JP2022033753A (ja)	2015-08-27	2021-11-08	トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用

Publications (3)

Publication Number	Publication Date
JP2018525430A JP2018525430A (ja)	2018-09-06
JP2018525430A5 true JP2018525430A5 (2)	2019-10-10
JP7334041B2 JP7334041B2 (ja)	2023-08-28

Family

ID=58100623

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2018511057A Active JP7334041B2 (ja)	2015-08-27	2016-08-25	トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用
JP2021182007A Pending JP2022033753A (ja)	2015-08-27	2021-11-08	トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2021182007A Pending JP2022033753A (ja)	2015-08-27	2021-11-08	トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用

Country Status (9)

Country	Link
US (2)	US11414428B2 (2)
EP (1)	EP3350188B1 (2)
JP (2)	JP7334041B2 (2)
KR (1)	KR20180048798A (2)
CN (1)	CN108349997B (2)
AU (2)	AU2016312848A1 (2)
CA (1)	CA2996681C (2)
WO (1)	WO2017034420A1 (2)
ZA (1)	ZA201800787B (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2996681C (en) *	2015-08-27	2024-04-09	Auckland Uniservices Limited	Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
CN108969522B (zh)	2017-06-05	2023-03-28	复旦大学	N-苄基色胺酮类衍生物作为色氨酸双加氧酶(tdo)抑制剂的用途
GB201809050D0 (en)	2018-06-01	2018-07-18	E Therapeutics Plc	Modulators of tryptophan catabolism
CN120004785A (zh) *	2018-07-03	2025-05-16	诺华制药股份有限公司	用于治疗与sting活性有关的疾病的化合物和组合物
EP4274824A1 (en)	2021-01-08	2023-11-15	IFM Due, Inc.	Heterobicyclic compounds having an urea or analogue and their compositions for treating conditions associated with sting activity
EP4052705A1 (en)	2021-03-05	2022-09-07	Universität Basel Vizerektorat Forschung	Compositions for the treatment of ebv associated diseases or conditions
MX2023010371A (es)	2021-03-05	2024-02-12	Univ Basel	Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb.
JP2025507981A (ja)	2022-03-04	2025-03-21	アンティドセラピューティクスインターナショナルソシエテアレスポンサビリテリミティー	トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の二重阻害剤と療法におけるそれらの使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001255410A1 (en)	2000-04-14	2001-10-30	Corvas International, Inc.	Substituted hydrazinyl heteroaromatic inhibitors of thrombin
CA2559105A1 (en)	2004-03-16	2005-09-29	Janssen Pharmaceutica N.V.	Benzisoxazoles
TW200633990A (en)	2004-11-18	2006-10-01	Takeda Pharmaceuticals Co	Amide compound
DE102005018389A1 (de)	2005-04-20	2006-10-26	Sanofi-Aventis Deutschland Gmbh	Azolderivate als Inhibitoren von Lipasen und Phospholipasen
DE102005038947A1 (de)	2005-05-18	2006-11-30	Grünenthal GmbH	Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
DE102005026194A1 (de) *	2005-06-06	2006-12-07	Grünenthal GmbH	Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
US10047066B2 (en)	2007-11-30	2018-08-14	Newlink Genetics Corporation	IDO inhibitors
US8461159B2 (en)	2008-11-25	2013-06-11	Jannsen Pharmaceutica BV	Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010068452A1 (en) *	2008-11-25	2010-06-17	Janssen Pharmaceutica Nv	Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
CA2754934A1 (en)	2009-03-10	2010-09-16	Gruenenthal Gmbh	Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators
MX2012009377A (es)	2010-02-11	2012-09-12	Univ Vanderbilt	Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica.
DK2595995T3 (en)	2010-07-22	2016-02-29	Basf Se	Herbicidal isoxazolo [5,4-b] pyridines
EP2802212B1 (en)	2012-01-12	2015-12-30	Basf Se	Herbicidal isoxazolo[5,4-b]pyridines
PL220630B1 (pl)	2012-12-28	2015-11-30	Inst Immunologii I Terapii Doświadczalnej Pan	Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny
SG11201507395PA (en)	2013-03-14	2015-10-29	Curadev Pharma Private Ltd	Inhibitors of the kynurenine pathway
US9931347B2 (en)	2013-12-03	2018-04-03	Iomet Pharma Ltd.	Pharmaceutical compound
KR102746352B1 (ko)	2014-08-13	2024-12-24	오클랜드 유니서비시즈 리미티드	트립토판 디옥시게나제 (ido1 및 tdo)의 억제제 및 치료에서 이들의 용도
CA2996681C (en) *	2015-08-27	2024-04-09	Auckland Uniservices Limited	Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
RU2619120C1 (ru)	2016-06-06	2017-05-12	Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет"	5-Хлор-3-(3-хлорфенилкарбоксамидо)-4,6-диметилизоксазоло[5,4-b]пиридин в качестве антидота 2,4-Д на подсолнечнике

2016
- 2016-08-25 CA CA2996681A patent/CA2996681C/en active Active
- 2016-08-25 AU AU2016312848A patent/AU2016312848A1/en not_active Abandoned
- 2016-08-25 EP EP16839685.1A patent/EP3350188B1/en active Active
- 2016-08-25 JP JP2018511057A patent/JP7334041B2/ja active Active
- 2016-08-25 CN CN201680063267.2A patent/CN108349997B/zh active Active
- 2016-08-25 WO PCT/NZ2016/050135 patent/WO2017034420A1/en not_active Ceased
- 2016-08-25 KR KR1020187008532A patent/KR20180048798A/ko not_active Withdrawn
- 2016-08-25 US US15/755,750 patent/US11414428B2/en active Active
2018
- 2018-02-06 ZA ZA2018/00787A patent/ZA201800787B/en unknown
2021
- 2021-08-03 AU AU2021212003A patent/AU2021212003B2/en active Active
- 2021-11-08 JP JP2021182007A patent/JP2022033753A/ja active Pending
2022
- 2022-08-15 US US17/888,281 patent/US20220411438A1/en not_active Abandoned

Publication	Publication Date	Title
JP2018525430A5 (2)	2019-10-10
JP2016506387A5 (2)	2016-07-21
JP2017537949A5 (2)	2019-02-07
JP2017504635A5 (2)	2018-03-08
JP2004527560A5 (2)	2005-08-18
RU2014105624A (ru)	2015-09-20	Соединения индазола, способ их применения и фармацевтическая композиция
JP2018537483A5 (2)	2020-01-16
JP2008509187A5 (2)	2008-10-02
RU2014135705A (ru)	2016-04-27	Фениколовые противобактериальные средства
JP2010513447A5 (2)	2011-02-10
JP2009536620A5 (2)	2010-06-17
SI2989100T1 (en)	2018-06-29	NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
JP2009506119A5 (2)	2009-10-15
JP2004529926A5 (2)	2005-07-28
JP2014037426A5 (2)	2014-04-10
RU2014141579A (ru)	2016-05-27	Гетероциклические соединения в качестве ингибиторов бета-лактамаз
JP2007502804A5 (2)	2007-09-27
JP2014503525A5 (2)	2014-07-10
JP2016512505A5 (2)	2017-04-13
JP2017526724A5 (2)	2018-10-25
RU2014115476A (ru)	2015-10-27	Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ
JP2005505618A5 (2)	2006-01-05
RU2019141734A (ru)	2021-06-23	Терапевтические соединения и композиции и способы их применения
JP2022500425A5 (2)	2022-08-09
JP2016531126A5 (2)	2017-09-28